Objective. There is a lack of consensus regarding the causes of the differences in the higher incidence of and the mortality from head and neck squamous cell carcinoma (HNSCC) in African Americans (AA) versus Caucasian Americans (CA). We examined a comprehensive array of risk factors influencing health and disease in an access-to-care, racially diverse, primary HNSCC cohort.
T here is abundant epidemiological evidence that selfidentified race/ethnicity is associated with differences in cancer incidence and mortality. The high mortality rate for head and neck squamous cell carcinoma (HNSCC) continues to be driven by the disparate unfavorable diagnosis and prognosis outcomes for African Americans (AA). [1] [2] [3] There is no consensus on the causes of the differences in the higher incidence of and the mortality from HNSCC for AA when compared with Caucasian Americans (CA), but they can include differences in access to care, stage at diagnosis, insurance, attitudes of health providers, and human papilloma virus (HPV) infection status. [3] [4] [5] [6] [7] [8] HPV is now regarded, in addition to tobacco and alcohol, 9 as a causative agent for some HNSCC 10 and an independent risk factor for oropharyngeal cancer. 11 Racial/ethnic differences such as genetic features, in combination with environmental factors, can also influence carcinogenic mechanisms and lead to biologically important differences in the molecular profile of a tumor. 12 Epidemiological and clinical studies using molecular markers indicate that racial differences in cancer types do exist, 12 supporting a systematic evaluation of these issues.
The objective of this study was to gain insights into differences in the higher incidence of and the mortality from HNSCC in AA versus CA through the examination of a comprehensive array of risk factors influencing health and disease in an access-to-care, racially diverse, primary HNSCC cohort.
Materials and Methods Study Design
Study cohort. The study cohort of 673 primary HNSCC was drawn from a large, clinically well-characterized multiethnic (40% AA) primary care patient population in the Detroit, Michigan, area. Patients 21 years or older with a primary HNSCC diagnostic biopsy in the Henry Ford Health System with available tumor tissue blocks were identified through tumor registry and ear, nose, and throat clinic records between 1986 and 2005. The Henry Ford Health System Tumor Registry (HFHS-TR) is certified by the Commission on Cancer of the American College of Surgeons and has been a division of the Department of Medical Records since the mid-1960s. All HFHS-TR registrars are registered health information technicians (RHITs) and have passed the national examination for RHIT. Follow-up spanned 4 to 23 years (through September 25, 2009 ). This study included only self-reported AA and CA HNSCC. Other ethnicities were excluded.
Risk factor variables. Risk variables included demographic, histopathology, and clinical/epidemiologic risk factors for a total of 23 nongene variables and are described in Tables 1  and 2 . Tumor DNA was interrogated for loss and gain of 113 genes with known involvement in HNSCC/cancer (gene panels p005, p006, p007; www.mlpa.com).
The Pathology Review Form recorded all squamous head and neck (SHN) diagnoses from a specific biopsy specimen ( Table 2 ). The SHN Medical Record Abstraction Form captured a patient's clinical, demographical, and epidemiological information, including smoking, alcohol, and comorbidity. Overall comorbidity was determined using the Adult Comorbidity Evaluation 27 (ACE-27) index for cancer patients. 13 The ACE-27 categorizes specific diseases into 1 of 3 grades: grade 1 (mild), grade 2 (moderate), and grade 3 (severe), based on organ decompensation and prognostic impact. Comorbidity scores include none = 0, mild = 1, moderate = 2, or severe = 3 and are assigned based on the highest ranked/graded single ailment. 14 Collection of clinical, epidemiological, and demographical data was conducted by experienced medical record abstractors trained in the use of study forms. Age cutoffs of \50 years, 51 to 65 years, and .65 years were set to capture younger patients and those in the Medicare group.
Health insurance payors included Blue Cross, Medicare, Medicaid, Health Alliance Plan (HAP; a health maintenance organization [HMO]), and other non-HAP HMOs (other HMO). Patients were categorized into treatment groups of surgery, radiation, and chemotherapy. This study was approved by the Henry Ford Health System Institutional Review Board committee.
Molecular Methods
Whole 5-mm tissue sections or microdissected tumor lesions and adjacent normal tissue when present were processed for DNA extraction. 15 DNA was interrogated for gene copy number alterations (losses and gains) using the multiplex ligation-dependent probe amplification assay (MLPA) as previously described. [16] [17] [18] [19] MLPA is a high-throughput assay allowing simultaneous interrogation of 41 genes using minute amounts (20 ng) of DNA. Validated using real-time polymerase chain reaction (PCR), it is ideally suited for DNA from formalin-fixed paraffin-embedded tissues. [16] [17] [18] [19] Gene gain and loss by MLPA concurred with chromosomal aberrations and provides a novel index to estimate the extent of genomic abnormality with disease progression. 16 Three gene probe panels, p005, p006, and p007 (www.mlpa.com), comprising 113 unique genes, were examined. The panels detect primarily oncogenes and tumor suppressor genes that are located at chromosomal segments that have been implicated in cancer and distributed throughout the genome. [16] [17] [18] [19] 
Statistical Methods
All analyses were done using SAS 9.2. Logistic regression modeling was used to examine risk factor differences between AA and CA HNSCC. The analysis started with testing for individual variable effects followed by inclusion of variable(s) of P \ .10 in the stepwise multivariable modeling process. Multivariable modeling is an analytical approach to increase model predictability (eg, c-index) based on a set of risk factors rather than a single factor. The risk factors retained in the final multivariable model become independent predictors after adjusting for the other covariate factors. The final multivariate model included variable(s) of P \ .05 with determination of the c-index estimation for goodness of fit. The c-index ranges from 0 to 1, where 1 indicates perfect fit and 0 none. The usual interpretation of the c-index is in context of prediction, but here it reflects the general amount of separation between AA and CA for the variables in the model.
Results
Of the 673 primary HNSCC cohort, 391 were CA and 282 AA (42%); the mean age was 64 years (SD, 12 years), with 14% 50 years or younger, 38% 51 to 65 years, and 48% .65 years of age. Demographic, histopathology, and clinical/ epidemiological variables examined in this study for AA and CA patients are presented in Tables 1 and 2 .
Of the 136 total variables (2 demographic, 11 histopathology, 10 clinical/epidemiology, 113 MLPA), univariate differences in race as AA and CA were noted for 39 risk factors (P \ .10). Of the 39 univariate factors, 25 were gene and 14 were nongene variables.
Multivariate modeling retained 7 variables (P \ .05) with a c-index of 0.81 ( Table 3) . Type of insurance such as HAP, Blue Cross, Medicaid, Medicare, and other HMO was a significant predictor of race. Insurance type (including Medicaid) was noted for 87% CA (339/391) and 88% AA (249/282). A larger proportion of the CA group (87%, 336/ 391) had private insurance (HAP, Medicare, Blue Cross, other HMO) as compared with 81% (228/282) of AA patients. With HAP as reference, AA were more likely to have Medicaid (OR = 24.5), Medicare (OR = 3.69), and other HMO (OR = 3.99). Insurance status by stage was not significant. AA were more likely to be unmarried (OR = 2.44). AA were more likely to be current and past smokers (OR = 2.83 and OR = 3.89, respectively). AA were more likely to have a tumor lymphocytic response, whether continuous rim or patchy infiltrate (OR = 6.12, OR = 7.83, respectively). Of the treatment types (surgery, radiation, chemotherapy), radiation (P = .020) and chemotherapy (P = .010) were univariate predictors of race as AA. Radiation remained in the final model; AA were more likely to receive radiation treatment than were CA (OR = 2.23). Radiation by stage was not significant (P = .09). With regard to tumor genetic alterations, AA tumors were more likely to have gain of SCYA3 (OR = 2.81) and less likely to have loss of SCYA3 (OR = 0.58) than CA tumors. For the CDKN2A gene, AA tumors were more likely to have loss of CDKN2A (OR = 1.47) when compared with CA tumors.
Discussion
There is considerable evidence to support the disproportionate increase in HNSCC incidence and mortality in AA as compared with CA. [1] [2] [3] 20 The age-adjusted incidence of head and neck cancers of the larynx and oral cavity and pharynx in AA in the United States between 2003 and 2007 was higher than in whites. 21 For the period 1975 to 2007, the death rates for all cancers combined continued to be substantially higher among AA than whites with improving rates for women. 21 The ability to dissect out factors that contribute to racial disparities, while gaining ground, continues to be challenging. Some reasons for this include a dearth of large multiethnic studies of primary HNSCC cohorts with sizable AA patients. Also, most studies have examined HNSCC outcomes in narrower contexts of a limited number of pathologic and clinical risk factors. This large multiethnic Detroit HNSCC study with 42% AA took a broader, more inclusive approach by examining many intertwined variables influencing health and disease.
Access to Care
Much of the disparities in HNSCC outcomes for AA, as in other cancers, are likely due to access to care barriers that prevent timely and high-quality medical care, resulting in later stage at diagnosis and inequalities in treatment. 3, 22, 23 In this study, although a majority of patients had some form of medical insurance, insurance type was a significant predictor of race. The primary health care environment of the HFHS is dominated by HAP, a nonprofit HMO serving more than 2800 Detroit-area employers and more than 580,000 members. Nearly half of the cohort (287/588) had Medicare, reflecting the age distribution of the 2 groups. When compared with CA, AA were significantly more likely to have Medicaid (8% AA, 1% CA), Medicare (58% AA, 42% CA), and other HMO types (13% AA, 6% CA). Stage at diagnosis, a significant univariate predictor (P = .003) for race (late stage: 66% AA, 54% CA), did not remain in the final multivariate model as an independent factor for race. The latter is likely because of the primary care environment of the HFHS and access to some form of insurance for most cohort subjects.
Marital Status
Quality of life and survival rates for head and neck cancer patients are better for married persons and those not living alone compared with unmarried persons and those living alone. 24 In our study, marital status was an independent predictor of race as AA versus CA (OR = 2.44) and a likely underlying contributing social factor for the observed disparate outcomes for AA as compared with CA with HNSCC in reported studies.
Smoking
Smoking is responsible for about 30% of all cancer deaths and is associated with increased risk of at least 16 types of cancer including HNSCC. 25 Unlike past decades in which the rate of adult smoking has been higher in AA than CA, in recent years these rates are more comparable. 21 Tobacco is an etiologic agent in some HNSCC, and in this study, smoking status as past (OR = 2.83) or current (OR = 2.44) was significantly associated with race as AA.
Radiation Treatment
In this cohort, radiation treatment was an independent predictor of race. AA were 2.2 times more likely to receive radiation than were CA. Fewer AA (43%) received surgery than CA (49%), and chemotherapy was a univariate predictor of race (P = .010: 28% AA received chemotherapy vs 19% of CA). This observation is interesting from 2 aspects. First, it suggests that treatment was likely not a barrier, given that 87% of AA had some type of insurance, similar to that of the CA group (86%). Second, although radiation by stage was not significant (P = .09), it remains suspect that late-stage disease contributed to chemoradiation and less surgery and requires validation in a larger 1:1 matched case (AA) and control (CA) study. 
Tumor Lymphocytic Response
In HNSCC, studies of lymphocytic response, a histologic parameter, have been based on the subjective observation of lymphocyte infiltration on hematoxylin and eosin-stained tissue sections. These earlier studies have indicated an inverse correlation between lymphocytic infiltrate, local recurrence, 26 potential for lymph node metastasis, 27 and survival. 28 In this study, presence of a lymphocytic response as a continuous rim or patchy infiltrate was an independent predictor of race. AA tumors were 6 to 7 times more likely than CA tumors to present with a lymphocytic response. The latter suggests a growing support for the dual roles of immune system cells, on one hand being summoned as first responders in local host defenses against tumors 29 and on the other hand being maneuvered into behaving as if they were healing a wound, 30 emitting growth factors that embolden the tumor into activities such as stimulating angiogenesis. 31 Molecular insights into these responses would greatly aid in our understanding of HNSCC pathogenesis and are further discussed in the section below.
Tumor Molecular Characteristics
Genetic alterations provide means of identifying tumor cells and defining changes that presumably determine biological differences from their normal counterparts. Molecular genetic prognosticators can influence prevention, diagnosis, appropriateness of adjuvant chemotherapy, and, possibly, the chemotherapeutic regimen of cancer patients. Dissecting out processes specific to the pathogenesis of malignancy can distill key genetic biomarkers of HNSCC etiology, transformation, and progression. In this study, the AA tumors were 1.4 times more likely to have loss of the CDKN2A gene as compared with CA tumors. The CDKN2A p14ARF, p16INK4a locus at 9p21, which generates 2 gene products, p16 and p14, 32, 33 has been linked to malignant progression in HNSCC. 34, 35 Loss of p16 expression by deletion, mutation, or hypermethylation is common in HNSCC 17, 36 and is associated with worse prognosis. 37 Also, tobacco-/alcohol-associated HNSCC appears to be associated with p16 down-regulation (as an early event) and the TP53 gene mutation resulting in p53 overexpression. 38 SCYA3, otherwise known as macrophage inflammatory protein-1a (MIP-1-a) or CCL3, belongs to the CC (b) subfamily of chemokines that recruit a variety of cells to sites of inflammation. 39 In oral squamous cell carcinoma, CCL3/ CCR1 appears to have dual roles of tumor lymph node metastasis and local host defense against tumor. 29 This was also demonstrated in hepatocelluar carcinoma progression 40 and supports multiple and opposite functions in tumorigenesis for the CCL3/CCR1 system.
In our study, the lack of fidelity of the SCYA3 gene with respect to loss and gain was an independent factor for race. AA tumors were almost 3 times more likely to have gain of SCYA3 and 57% less likely to have loss when compared with CA tumors. This observation suggests a tantalizing connection to the finding that AA tumors were almost 6 to 7 times more likely to have presence of lymphocytic response, when presenting as a patchy infiltrate or as a continuous rim, when compared with CA tumors. Immunohistochemistry to correlate CCL3/CCR1 and SCYA3 copy number with presence or absence of lymphocytic response in AA and CA in this cohort is a next step.
Conclusion
Understanding and accounting for factors contributing to differences in HNSCC racial groups should provide much needed insights into disparities of incidence and mortality in AA. The contribution of HPV and p16 involvement was not evaluated, and this was a study limitation. Major strengths of this study include the large multiethnic primary HNSCC cohort with 42% AA and a comprehensive examination of patient and tumor variables influencing health and disease. We found significant differences between AA and CA HNSCC for histopathology, treatment, smoking, marital status, type of insurance, and tumor gene copy number alterations. Our data reiterate that for HNSCC, as in the case of other complex diseases, tumor genetics or biology is only one of many potential contributors to differences among racial groups.
